---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-065274"
form_type: "8-K"
ticker: "MLTX"
cik: "0001821586"
company_name: "MoonLake Immunotherapeutics"
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T18:54:06.732186+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# MoonLake reports Q2 cash $501.8M after $460M offering; positive Phase 2 MIRA data in HS

## Summary
- Raised ~$460M gross in upsized public offering (8M shares at $50); cash & equivalents $501.8M at June 30, 2023.
- Positive Phase 2 MIRA trial met primary endpoint HiSCR75 at week 12; sonelokimab showed highest clinical activity among tested therapies.
- Completed randomization of 200 patients in Phase 2 ARGO PsA trial ahead of schedule; top-line 12-week data expected H1 Nov 2023.
- R&D expenses $8.7M, G&A $4.5M for Q2 2023; no revenue (clinical-stage biotech).
- Upcoming catalysts: MIRA 24-week data mid-Oct, ARGO 12-week data Nov, End of Phase 2 FDA meeting Dec 2023.

## SEC filing metadata
- accession: 0001213900-23-065274
- form_type: 8-K
- ticker: MLTX
- cik: 0001821586
- company_name: MoonLake Immunotherapeutics
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821586/000121390023065274/0001213900-23-065274-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821586/000121390023065274/ea183237-8k_moonlake.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-065274
- JSON: https://secwatch.observer/filing/0001213900-23-065274.json
- Plain text: https://secwatch.observer/filing/0001213900-23-065274.txt

## Key facts
- Earnings Releases
  MoonLake Immunotherapeutics reported financial results for the quarter ended June 30, 2023.
  - Period: the quarter ended June 30, 2023
  - Result: reported results
  source text: Moonlake Immunotherapeutics (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1821586/000121390023065274/0001213900-23-065274-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.